Lesley Mathews Griner
Overview
Explore the profile of Lesley Mathews Griner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbott K, Ali A, Casalena D, Do B, Ferreira R, Cheah J, et al.
Cell Chem Biol
. 2023 Sep;
30(9):1156-1168.e7.
PMID: 37689063
A challenge for screening new anticancer drugs is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a...
2.
Abbott K, Ali A, Casalena D, Do B, Ferreira R, Cheah J, et al.
bioRxiv
. 2023 Mar;
PMID: 36909640
A challenge for screening new candidate drugs to treat cancer is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell...
3.
Zhou H, Blevins M, Hsu J, Kong D, Galbraith M, Goodspeed A, et al.
Cancer Res
. 2020 Apr;
80(12):2689-2702.
PMID: 32341035
Metastasis is the major cause of mortality for patients with cancer, and dysregulation of developmental signaling pathways can significantly contribute to the metastatic process. The Sine oculis homeobox homolog 1...
4.
Kaur S, Schwartz A, Jordan D, Soto-Pantoja D, Kuo B, Elkahloun A, et al.
Front Oncol
. 2019 Oct;
9:994.
PMID: 31632920
Knockdown or gene disruption of the ubiquitously expressed cell surface receptor CD47 protects non-malignant cells from genotoxic stress caused by ionizing radiation or cytotoxic chemotherapy but sensitizes tumors in an...
5.
Fontelonga T, Jordan B, Nunes A, Barraza-Flores P, Bolden N, Wuebbles R, et al.
Hum Mol Genet
. 2019 Feb;
28(13):2120-2132.
PMID: 30806670
Duchenne muscular dystrophy (DMD) is a lethal, muscle degenerative disease causing premature death of affected children. DMD is characterized by mutations in the dystrophin gene that result in a loss...
6.
Griner L, Gampa K, Do T, Nguyen H, Farley D, Hogan C, et al.
J Vis Exp
. 2018 Sep;
(139).
PMID: 30247463
Cancer cells have routinely been cultured in two dimensions (2D) on a plastic surface. This technique, however, lacks the true environment a tumor mass is exposed to in vivo. Solid...
7.
Feliz-Mosquea Y, Christensen A, Wilson A, Westwood B, Varagic J, Melendez G, et al.
Breast Cancer Res Treat
. 2018 Jul;
172(1):69-82.
PMID: 30056566
Background: A perennial challenge in systemic cytotoxic cancer therapy is to eradicate primary tumors and metastatic disease while sparing normal tissue from off-target effects of chemotherapy. Anthracyclines such as doxorubicin...
8.
Frankowski K, Wang C, Patnaik S, Schoenen F, Southall N, Li D, et al.
Sci Transl Med
. 2018 May;
10(441).
PMID: 29769289
Metastasis remains a leading cause of cancer mortality due to the lack of specific inhibitors against this complex process. To identify compounds selectively targeting the metastatic state, we used the...
9.
Antignani A, Griner L, Guha R, Simon N, Pasetto M, Keller J, et al.
PLoS One
. 2016 Aug;
11(8):e0161415.
PMID: 27556570
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little...
10.
Mukhopadhyay R, Roy S, Venkatadri R, Su Y, Ye W, Barnaeva E, et al.
PLoS Pathog
. 2016 Jun;
12(6):e1005717.
PMID: 27336364
Infection with human cytomegalovirus (HCMV) is a threat for pregnant women and immunocompromised hosts. Although limited drugs are available, development of new agents against HCMV is desired. Through screening of...